dermovat 0,5 mg/ml kutanopløsning
nordic prime aps - clobetasolpropionat - kutanopløsning - 0,5 mg/ml
ravicti
immedica pharma ab - glycerolphenylbutyrat - urinstofcyklusforstyrrelser, født - andre alimentary tract and metabolism produkter, - ravicti er indiceret til brug som supplerende behandling til kroniske management af patienter med urinstof-cyklus forstyrrelser (ucds), herunder fejl og mangler af carbamoyl phosphat-syntase-jeg (cps), ornithin carbamoyltransferase (otc), argininosuccinate synthetase (ass), argininosuccinate lyase (asl), arginase jeg (arg) og ornithin translocase mangel hyperornithinaemia-hyperammonaemia homocitrullinuria syndrom (hhh), der ikke kan håndteres af kosten protein restriktion og/eller aminosyre tilskud alene. ravicti skal anvendes med kosten protein restriktion og, i nogle tilfælde, kosttilskud (e. , essentielle aminosyrer, arginin, citrullin, proteinfri kalorietilskud).
solymbic
amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - immunosuppressiva - se venligst afsnit 4. 1 i resuméet af produktegenskaber i produktinformationsdokumentet.
tygacil
pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibakterielle midler til systemisk brug, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler.. hensigtsmæssig brug af antibakterielle midler..
zinforo
pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibakterielle midler til systemisk brug, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.
avelox 400 mg filmovertrukne tabletter
bayer ab - moxifloxacinhydrochlorid - filmovertrukne tabletter - 400 mg
avelox 1,6 mg/ml infusionsvæske, opløsning
bayer ab - moxifloxacinhydrochlorid - infusionsvæske, opløsning - 1,6 mg/ml
brufen 400 mg filmovertrukne tabletter
viatris aps - ibuprofen - filmovertrukne tabletter - 400 mg
brufen retard 800 mg depottabletter
viatris aps - ibuprofen - depottabletter - 800 mg
brufen retard 800 mg depottabletter
2care4 aps - ibuprofen - depottabletter - 800 mg